J Gen Virol Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

J Gen Virol 86 (2005), 1001-1007; DOI 10.1099/vir.0.80607-0

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lagrange, M.
Right arrow Articles by Deryckere, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lagrange, M.
Right arrow Articles by Deryckere, F.
Agricola
Right arrow Articles by Lagrange, M.
Right arrow Articles by Deryckere, F.
© 2005 Society for General Microbiology

Short Communication

Binding of human papillomavirus 16 E6 to p53 and E6AP is impaired by monoclonal antibodies directed against the second zinc-binding domain of E6

Magali Lagrange1, Sebastian Charbonnier1, Georges Orfanoudakis1, Philip Robinson1, Katia Zanier1, Murielle Masson1, Yves Lutz2,{dagger}, Gilles Trave1, Etienne Weiss1 and François Deryckere1

1 UMR7100, Ecole Supérieure de Biotechnologie de Strasbourg, Pole API, boulevard Sébastien Brant, 67412 Illkirch Cedex, France
2 IGBMC, CNRS/INSERM/ULP, 1 rue Laurent Fries, BP 10142, 67404 Illkirch Cedex, France

Correspondence
François Deryckere
francois.deryckere{at}esbs.u-strasbg.fr

The E6 protein of cancer-associated human papillomavirus type 16 (16E6) binds to p53 and, in association with E6AP, promotes its degradation through the ubiquitin–proteasome pathway. The aim of this work was to develop monoclonal antibodies against 16E6 and to test their effect on the binding of 16E6 to p53 and E6AP, and on the degradation of p53. It was shown that an antibody directed against the N terminus of 16E6 inhibited E6AP-dependent binding to p53 and degradation of p53, whereas two different antibodies directed to the second zinc-binding domain of 16E6 reduced 16E6 E6AP-independent binding to p53 and binding to E6AP but not degradation of p53.

{dagger}Present address: INSERM U 338, Centre de Neurochimie, 5 rue Blaise Pascal, 67084 Strasbourg, France.




This article has been cited by other articles:


Home page
 J. Virol.Home page
B. Cooper, N. Brimer, and S. B. Vande Pol
Human Papillomavirus E6 Regulates the Cytoskeleton Dynamics of Keratinocytes through Targeted Degradation of p53
J. Virol., November 15, 2007; 81(22): 12675 - 12679.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. Courtete, A.-P. Sibler, G. Zeder-Lutz, D. Dalkara, M. Oulad-Abdelghani, G. Zuber, and E. Weiss
Suppression of cervical carcinoma cell growth by intracytoplasmic codelivery of anti-oncoprotein E6 antibody and small interfering RNA
Mol. Cancer Ther., June 1, 2007; 6(6): 1728 - 1735.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
M. Jing, J. Bohl, N. Brimer, M. Kinter, and S. B. Vande Pol
Degradation of Tyrosine Phosphatase PTPN3 (PTPH1) by Association with Oncogenic Human Papillomavirus E6 Proteins
J. Virol., March 1, 2007; 81(5): 2231 - 2239.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
INT J SYST EVOL MICROBIOL MICROBIOLOGY J GEN VIROL
J MED MICROBIOL ALL SGM JOURNALS
Copyright © 2005 by the Society for General Microbiology.